MUMBAI, INDIA--(Marketwired - Feb 10, 2014) - Groupe Athena, Inc. (OTC Pink: GATA) today posted their quarterly results for the three months ending December 31, 2013. The company reported revenues of $17,961,452 which is an increase of 21% when compared to the corresponding period in 2012 and represents the strongest 6 month earnings period in the company's history. Operating income for the quarter was also strong at $3, 097,791, an increase of over 26% from $2.45 million for the same period in 2012.
Net income after taxes and depreciation for the period was $2,083,606 or $.044 per share.
With regard the continued strong growth, the company's President, Ms. D Purohit, stated, "I can't put into words how exciting it is to see our dreams become reality. Our core business is thriving and our expansion plans are proceeding as expected. We fully expect 2014 to be a breakout year for Groupe Athena, Inc."
The company reiterates that the strong increase in operating income is due to the continued increases in gross margins and they anticipate further increases as more work is transitioned in-house. Operating margins are approaching 20% currently and management remains committed to attain 40% gross margins over the next few years.
The company's order position also remains very healthy and management expects record total revenues of at least $65 million for the current fiscal year.
Cash and cash equivalents are at record levels for the company and continue to grow and debt remains virtually non-existent.
To review the complete quarterly report please go to www.otcmarkets.com/stock/GATA/quote and click on "Financials."
The Indian pharmaceutical industry is increasingly focusing on exports to the United States and Europe and GATA is well positioned to help them get their products approved by the respective governing bodies for sales in both regions. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.
About Groupe Athena, Inc.
Groupe Athena, Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.
The company has a research and marketing facility in India that currently employs 18 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.